Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 4/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.65 |
| ▸ | CA2 | P00918 | 9/20 | 0.62 |
| ▸ | CA1 | P00915 | 8/20 | 0.62 |
| ▸ | CA9 | Q16790 | 6/20 | 0.62 |
| ▸ | CA12 | O43570 | 4/20 | 0.62 |
| ▸ | CA4 | P22748 | 3/20 | 0.62 |
| ▸ | CA6 | P23280 | 3/20 | 0.62 |
| ▸ | CA5A | P35218 | 3/20 | 0.62 |
| ▸ | CA7 | P43166 | 3/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.62 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.62 |
| ▸ | CA3 | P07451 | 1/20 | 0.56 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18359163 | 0.83 | CA2 (0.62) | SOS1PTGS1PTGS2CA2CA1 | |
| SCHEMBL4618133 | 0.81 | SOS1 (0.54) | SOS1PTGS1PTGS2CA2CA1 | |
| SCHEMBL67606 | 0.81 | SOS1 (0.50) | SOS1PTGS1PTGS2CA2 | |
| SCHEMBL301718 | 0.80 | CA2 (0.69) | SOS1PTGS1PTGS2CA2CA1 | |
| SCHEMBL793608 | 0.80 | CA2 (0.69) | PTGS1PTGS2CA2CA1CA9 | |
| SCHEMBL6721570 | 0.79 | PTGS2 (1.00) | PTGS1PTGS2 | |
| SCHEMBL6741781 | 0.79 | AGTR1 (0.49) | SOS1PTGS1PTGS2CA2CA1 | |
| Silver SCHEMBL6115022 | 0.79 | SOS1 (0.49) | SOS1PTGS1PTGS2CA2 | |
| SCHEMBL585689 | 0.79 | PTGS2 (0.65) | SOS1PTGS1PTGS2 | |
| SCHEMBL6763102 | 0.79 | MEN1 (0.54) | SOS1PTGS1PTGS2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101516837-A | Sulfonamide derivatives | HOFFMANN LA ROCHE (CH) | 2009-08-26 | — | — | CN | claimed |
| JP-2007511596-A | — | — | 2007-05-10 | — | — | JP | claimed |
| EP-1687309-A1 | PYRROLOPYRIMIDINE COMPOUNDS USEFUL IN TREATMENT OF CANCER | Pfizer Products Inc. (US) | 2006-08-09 | — | — | EP | claimed |
| WO-2005047289-A1 | PYRROLOPYRIMIDINE COMPOUNDS USEFUL IN TREATMENT OF CANCER | PFIZER PRODUCTS INC. (US) | 2005-05-26 | — | — | WO | claimed |
| US-20030125328-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-07-03 | — | — | US | claimed |
| US-20260028356-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | ABBVIE INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250066388-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | ABBVIE INC (US) | 2025-02-27 | — | — | US | disclosed |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2025-01-16 | — | — | US | disclosed |
| EP-4474383-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2024-12-11 | — | — | EP | disclosed |
| CN-119053610-A | 1,3,4, 7-Tetrahydro-2H-pyrrolo [3',2':5,6] pyrido [2,3-b ] [1,4] oxazepine Bcl-2 inhibitors | 艾伯维公司 | 2024-11-29 | — | — | CN | disclosed |
| US-6608095-B2 | Sulfonylbenzene and sulfonamidobenzene compounds which inhibit COX-2; treatment of a medical condition in which prostaglandins are implicated as pathogens | PFIZER INC. | 2003-08-19 | — | — | US | disclosed |
| US-20020045654-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | ANDO KAZUO (JP) | 2002-04-18 | — | — | US | disclosed |
| US-6294558-B1 | ANTIINFLAMMATORY AGENTS AND PROSTAGLANTINS | PFIZER INC. | 2001-09-25 | — | — | US | disclosed |
| EP-1086097-A1 | SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER INC. (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999064415-A1 | SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-12-16 | — | — | WO | disclosed |
| EP-0510526-B1 | Use of sulfonamides as drug and new sulfonamides | HOFFMANN LA ROCHE (CH) | 1996-12-04 | — | — | EP | disclosed |
| US-5270313-A | Treatment of circulatory disorders | HOFFMANN-LA ROCHE INC. (US) | 1993-12-14 | — | — | US | disclosed |
| EP-0510526-A1 | Use of sulfonamides as drug and new sulfonamides | F.HOFFMANN-LA ROCHE & CO. AKTIENGESELLSCHAFT (CH) | 1992-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028356-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | BCL9L, BCL2L2, BCL2L1 | SOS1 347/4885PTGS1 1044/4885PTGS2 744/4885 |
| US-20030125328-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | SOS1 3264/4885PTGS1 2773/4885PTGS2 3720/4885 |
| US-20250066388-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | BCL9L, BCL2L1, BCL2L2 | SOS1 422/4885PTGS1 178/4885PTGS2 211/4885 |
| US-20020045654-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | CNR1, PTGER1, PTGS1 | SOS1 1340/4885PTGS1 3/4885PTGS2 30/4885 |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | SOS1 2641/4885PTGS1 257/4885PTGS2 171/4885 |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | BCL2, BAX, BCL2L1 | SOS1 1466/4885PTGS1 2722/4885PTGS2 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.